[go: up one dir, main page]

EP3508214A4 - Therapeutisches mittel gegen ischämische erkrankungen - Google Patents

Therapeutisches mittel gegen ischämische erkrankungen Download PDF

Info

Publication number
EP3508214A4
EP3508214A4 EP17824332.5A EP17824332A EP3508214A4 EP 3508214 A4 EP3508214 A4 EP 3508214A4 EP 17824332 A EP17824332 A EP 17824332A EP 3508214 A4 EP3508214 A4 EP 3508214A4
Authority
EP
European Patent Office
Prior art keywords
therapeutic agent
ischemic diseases
ischemic
diseases
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17824332.5A
Other languages
English (en)
French (fr)
Other versions
EP3508214A1 (de
Inventor
Teruyuki Komatsu
Ryosuke Funaki
Takeo Abumiya
Masayuki GEKKA
Kiyohiro Houkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chuo University
Original Assignee
Chuo University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chuo University filed Critical Chuo University
Publication of EP3508214A1 publication Critical patent/EP3508214A1/de
Publication of EP3508214A4 publication Critical patent/EP3508214A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP17824332.5A 2016-07-06 2017-07-06 Therapeutisches mittel gegen ischämische erkrankungen Withdrawn EP3508214A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016134478 2016-07-06
PCT/JP2017/024857 WO2018008729A1 (ja) 2016-07-06 2017-07-06 虚血性疾患の治療剤

Publications (2)

Publication Number Publication Date
EP3508214A1 EP3508214A1 (de) 2019-07-10
EP3508214A4 true EP3508214A4 (de) 2020-05-13

Family

ID=60912768

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17824332.5A Withdrawn EP3508214A4 (de) 2016-07-06 2017-07-06 Therapeutisches mittel gegen ischämische erkrankungen

Country Status (4)

Country Link
US (1) US20190328892A1 (de)
EP (1) EP3508214A4 (de)
JP (1) JP7016124B2 (de)
WO (1) WO2018008729A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113975378A (zh) * 2021-11-19 2022-01-28 润方（北京）生物医药研究院有限公司 一种聚合血红蛋白在制备治疗缺血性脑卒中药物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012117688A1 (ja) * 2011-03-01 2012-09-07 学校法人中央大学 ヘモグロビン－アルブミン複合体、並びに該複合体を含む人工血漿増量剤及び人工酸素運搬体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403575A (en) 1991-12-12 1995-04-04 Hemagen/Pfc Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them
US5334706A (en) 1992-01-30 1994-08-02 Baxter International Administration of low dose hemoglobin to increase perfusion
CA2215697C (en) 1995-03-23 2009-08-18 Biopure Corporation Stable polymerized hemoglobin blood-substitute
AR001654A1 (es) * 1995-04-19 1997-11-26 Univ East Carolina Método para la descontaminacion microbiana de plaquetas sanguineas
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
JP2006516994A (ja) 2003-01-29 2006-07-13 ノースフィールド ラボラトリーズ、インコーポレイテッド テトラマーの量を低下させた重合ヘモグロビン溶液及び調製するための方法
JP2011001271A (ja) 2009-06-16 2011-01-06 Tomio Ota 輸液

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012117688A1 (ja) * 2011-03-01 2012-09-07 学校法人中央大学 ヘモグロビン－アルブミン複合体、並びに該複合体を含む人工血漿増量剤及び人工酸素運搬体
US20130338342A1 (en) * 2011-03-01 2013-12-19 Chuo University Hemoglobin-albumin complex, and artificial plasma expander and artificial oxygen carrier containing the complex

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAIKI TOMITA ET AL: "Covalent Core-Shell Architecture of Hemoglobin and Human Serum Albumin as an Artificial O 2 Carrier", BIOMACROMOLECULES, vol. 14, no. 6, 1 January 2013 (2013-01-01), US, pages 1816 - 1825, XP055557331, ISSN: 1525-7797, DOI: 10.1021/bm400204y *
HARUKI RISA ET AL: "12778: Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute", SCIENTIFIC REPORTS,, vol. 5, 29 July 2015 (2015-07-29), pages 12778 - 1, XP009519489, ISSN: 2045-2322, DOI: 10.1038/SREP12778 *
KOMATSU ET AL: "Jinko Sanso Unpantai ''HemoActTM'' no Kaihatsu = [Development of artificial oxygen carrier "HemoActTM"]", vol. 22, no. 1, 1 January 2014 (2014-01-01), pages 11, XP009513595, ISSN: 1341-1594, Retrieved from the Internet <URL:https://www.blood-sub.jp/backnumber.php> *
See also references of WO2018008729A1 *

Also Published As

Publication number Publication date
EP3508214A1 (de) 2019-07-10
US20190328892A1 (en) 2019-10-31
JP7016124B2 (ja) 2022-02-04
WO2018008729A1 (ja) 2018-01-11
JPWO2018008729A1 (ja) 2019-04-25

Similar Documents

Publication Publication Date Title
HK1256383A1 (zh) 治療劑
DK3463465T3 (da) Exosomer omfattende terapeutiske polypeptider
EP3423109A4 (de) Therapie für frontotemporale demenz
MA47521A (fr) Agents thérapeutiques pour maladies neurodégénératives
EP3299001A4 (de) Sitzartiger rehabilitationsroboter zum gehen
EP3280421A4 (de) Pharmazeutische zusammensetzungen für eine kombinationstherapie
EP3349796A4 (de) Therapeutische kombinationen mit anti-folr1-immunkonjugaten
MA39483A (fr) Agents thérapeutiques cibles
IL270916A (en) Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
SI4119569T1 (sl) Konjugirane protismiselne spojine za uporabo v terapiji
EP3723488A4 (de) Therapeutische bakteriozine
GB201603104D0 (en) Therapeutic agents
EP3478480A4 (de) Dualer bonder
EP3630078A4 (de) Chemoembolisationsmittel
EP3307268A4 (de) Substituierte phenyloxazolidinone für antimikrobielle therapie
MA43587A (fr) Arnm thérapeutiques codant pour des anticorps anti-ctla-4
IL262851A (en) Combination prime: boost therapy
DK3408265T3 (da) Terapeutiske forbindelser
EP3573617A4 (de) Therapeutikum für lebererkrankungen
HUE060732T2 (hu) Terápiás szer fibrózisra
EP3449912A4 (de) Schmelztablette
EP3518957C0 (de) Therapeutisches protein
LT3448382T (lt) Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti
EP3371210A4 (de) Kombinationstherapie für maligne erkrankungen
GB201700553D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200409

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/62 20170101ALI20200403BHEP

Ipc: A61P 9/10 20060101ALI20200403BHEP

Ipc: A61K 38/42 20060101AFI20200403BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

17Q First examination report despatched

Effective date: 20240802

18W Application withdrawn

Effective date: 20240812